Synthesis and Evaluation of Pyridinyltriazoles as Inhibitors of p38 MAP Kinase

Authors

  • Farzin Hadizadeh Biotechnology Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran|School of Pharmacy, Mashhad University of Medical Sciences Mashhad, Iran
  • Fatemeh Abdol Abadi Medical Toxicology Research Centre, Mashhad University of Medical Sciences Mashhad, Iran
  • Jamal Shamsara School of Pharmacy, Mashhad University of Medical Sciences Mashhad, Iran
  • Mahmoud Shahraki School of Pharmacy, Mashhad University of Medical Sciences Mashhad, Iran
  • Seyed Adel Moallem Pharmaceutical Sciences Research Centre, Mashhad University of Medical sciences Mashhad, Iran|Medical Toxicology Research Centre, Mashhad University of Medical Sciences Mashhad, Iran|School of Pharmacy, Mashhad University of Medical Sciences Mashhad, Iran
Abstract:

Objective(s) Inhibitors of p38 MAP kinase are considered as suitable target in the treatment of inflammatory diseases such as rheumatoid arthritis and bowel inflammatory diseases. The development of 5-alkylthio-1-aryl-2-(4-pyridinyl) triazoles as inhibitors of p38 MAP kinase is described. These are analogues of 4- pyridinyl imidazole p38 MAP kinase inhibitor reported by Merck Research Laboratories, in which imidazole ring has been replaced with triazole. Materials and Methods Reaction of pyridine-4-carboxylic acid hydrazide 1 and arylisothiocyanate (2a, b) gave the intermediate thiourea derivative 3a, b (Figure 2). Refluxing  of the latter in aqueous saturated sodium carbonate gave 1-aryl-5-mercapto-2-(4-pyridinyl) triazoles 4a, b. Treatment of 4a, b with alkyl iodide afforded the desired 5-alkylthio-1-aryl-2-(4-pyridinyl) triazoles (5a-d). P38 MAP kinase inhibitory activity of the synthesized compounds was evaluated in vitro by ELISA method and also by molecular docking. Results Compound 5c at 1 µM concentration and compound 5d at 1 µM and 10 µM significantly inhibited the p38 phosphorylation. These inhibitory effects are equal to those of standard compound SB202190 and no significant differences were observed. Conclusion We demonstrated that both tested compounds have inhibitory effect on p38 MAP kinase and we did not find significant difference between their inhibitory effects and those of standard inhibitor SB202190.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

synthesis and evaluation of pyridinyltriazoles as inhibitors of p38 map kinase

objective(s) inhibitors of p38 map kinase are considered as suitable target in the treatment of inflammatory diseases such as rheumatoid arthritis and bowel inflammatory diseases. the development of 5-alkylthio-1-aryl-2-(4-pyridinyl) triazoles as inhibitors of p38 map kinase is described. these are analogues of 4- pyridinyl imidazole p38 map kinase inhibitor reported by merck research laborator...

full text

Application of 3D-QSAR on a Series of Potent P38-MAP Kinase Inhibitors

One of the most applied methods in drug industry for development of new drugs is 3D-QSAR methodology. As p38-mitogen-activated protein kinase (p38-MAPK) plays a crucial role in regulating the production of such proinflammatory cytokines as tumor necrosis factor-α (TNF-α) and interleukin-1, emerging as an attractive target for new anti-inflammatory agents, we used a 3D-QSAR based method of Compa...

full text

Synthesis and Evaluation of Ethyl 2,4-dioxo-4-arylbutanoate Derivatives as Src Kinase Inhibitors

In this work, different ethyl 2,4-dioxo-4-arylbutanoate derivatives were prepared and evaluated for their Src Kinase inhibitory activity. For this purpose, the appropriate substituted acetophenone derivatives reacted with diethyl oxalate in the presence of sodium ethoxide in dried ethanol to give the corresponding products. All compounds showed moderate activities comparing with staurosporine a...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 15  issue 4

pages  945- 950

publication date 2012-07-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023